Sansure Biotech Inc (Sansure) is a US$1.4bn market capitalisation in vitro diagnostic solutions company listed on Shanghai Stock Exchange
Mpox virus footprint has significant overlap with key markets where VivoPower operates, including the the Asia Pacific region, Australasia, Africa and the Middle East
The Singapore government has already introduced quarantine measures to contain the spread of the Mpox virus, with risk of other countries following suit
Distribution agreement is part of VivoPower’s business continuity planning protocols aimed at safeguarding employees, as well as facilitating distribution and supply to valued partners and customers
As a certified B Corporation, VivoPower is committed to the triple bottom line of People, Planet, and Profit; selected VivoPower management to fund pro bono distribution to disadvantage communities
VivoPower intends to reinvest any surplus profits and cash generated from Mpox distribution agreements into its core sustainable energy solutions business
VivoPower has announced a distribution heads of agreement with Sansure Biotech for the distribution and supply of Mpox diagnostic tests and detection kits to cover Singapore, Hong Kong and Australia, with other markets under consideration.
This proactive initiative is part of VivoPower’s business continuity planning (BCP) protocols to provide preventative measures for its own team and to supply valued partners and customers in the aforementioned market. The heads of agreement is non binding but both parties will work towards finalising definitive documents.
As a certified B Corporation, VivoPower is committed to the triple bottom line of People, Planet, and Profit. In this regard, VivoPower has consistently prioritised not just the professional growth of its teams, but also their safety and health.
In addition, VivoPower’s chairman and chief executive officer, as well as certain other executive leadership team members, will contribute their own funds to enable pro bono distribution of Mpox diagnostic and detection testing solutions to charitable organisations in selected markets that in turn provide support to impoverished and underserved communities.
The World Health Organization declared the Mpox outbreak a public health emergency of international concern on 14 August 2024, the highest alert under international health law.
As of June 2024, according to the United Nations, there have been 99,176 confirmed cases and 208 deaths reported across 116 countries including several of VivoPower’s markets, with Africa experiencing the highest transmission rates.
To read our full press release, and to keep up with all of VivoPower’s releases, visit our Press Releases page.
About Sansure Biotech
Established in 2008, Sansure Biotech Inc is a public company listed on the Shanghai Stock Exchange with over 2,000 employees and a market capitalisation in excess of US$1bn. It is an in vitro diagnostic solution provider integrating diagnostic reagents, instruments and independent clinic laboratory services with its own innovative gene technology as its core.
Contact
Shareholder Enquiries
